Literature DB >> 10195394

Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.

A Glaessl1, A K Bosserhoff, R Buettner, U Hohenleutner, M Landthaler, W Stolz.   

Abstract

During successive cell divisions of mortal cells the length of the telomeres (TTAGGG repeats in vertebrates) at the end of chromosomes decreases. It has been suggested that this process is responsible for cellular senescence. Expression of the ribonucleoprotein telomerase appears to prevent shortening of telomeres in germ-line cells and cancer cells. The purpose of this study was to investigate telomerase activity in melanocytic lesions and its possible role in the multi-step tumor progression model of malignant melanoma. To quantify the level of telomerase activity both in cultured cells and in fresh tissue samples the TRAP (telomeric repeat amplification protocol) ELISA was used. Eight cell lines of malignant melanoma, 3 primary cultures of fibroblasts, 36 melanocytic naevi, 5 atypical melanocytic naevi, 3 Spitz's naevi, 31 primary malignant melanomas and 13 metastases of malignant melanomas were investigated. Also 34 samples of skin (22 samples of perilesional skin and 12 samples of normal skin) were analysed. In our experiments all melanoma cell lines were strongly positive, whereas in fibroblasts telomerase activity could not be detected. Of the primary melanomas and metastatic melanomas, 90.3% and 92.3%, respectively, were strongly positive, and of the atypical melanocytic naevi, 80% were positive. Of the 36 common melanocytic naevi only 10 (27.7%) expressed weak telomerase activity and of the 34 samples of human skin, 4 (11.7%) expressed very weak telomerase activity. Our results indicate that telomerase activity increases from benign melanocytic naevi to atypical naevi and further to malignant melanoma and metastatic melanoma cells, and therefore may play a role in tumour initiation and progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195394     DOI: 10.1007/s004030050387

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  12 in total

1.  Integrated nanosensors to determine levels and functional activity of human telomerase.

Authors:  J Manuel Perez; Jan Grimm; Lee Josephson; Ralph Weissleder
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

2.  Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the beta deletion variant.

Authors:  Lisa F Lincz; Lisa-Maree Mudge; Fiona E Scorgie; Jennette A Sakoff; Christopher S Hamilton; Michael Seldon
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

Review 3.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

Review 4.  Telomerase promoter mutations in cancer: an emerging molecular biomarker?

Authors:  João Vinagre; Vasco Pinto; Ricardo Celestino; Marta Reis; Helena Pópulo; Paula Boaventura; Miguel Melo; Telmo Catarino; Jorge Lima; José Manuel Lopes; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  Virchows Arch       Date:  2014-07-22       Impact factor: 4.064

Review 5.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

6.  Telomerase activity in melanocytic lesions: A potential marker of tumor biology.

Authors:  P Rudolph; C Schubert; S Tamm; K Heidorn; A Hauschild; I Michalska; S Majewski; G Krupp; S Jablonska; R Parwaresch
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 7.  [The dysplastic nevus. Separate entity, melanoma precursor or diagnostic dilemma?].

Authors:  A Roesch; M Landthaler; T Vogt
Journal:  Hautarzt       Date:  2003-09       Impact factor: 0.751

8.  Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression.

Authors:  Julia K Soo; Alastair D Mackenzie Ross; David M Kallenberg; Carla Milagre; W Heung Chong; Jade Chow; Lucy Hill; Stacey Hoare; Rebecca S Collinson; Mehnaz Hossain; W Nicol Keith; Richard Marais; Dorothy C Bennett
Journal:  Pigment Cell Melanoma Res       Date:  2011-04-20       Impact factor: 4.693

9.  Nevus senescence.

Authors:  Andrew L Ross; Margaret I Sanchez; James M Grichnik
Journal:  ISRN Dermatol       Date:  2011-06-22

10.  Unusually stable abnormal karyotype in a highly aggressive melanoma negative for telomerase activity.

Authors:  Sarantis Gagos; George Papaioannou; Maria Chiourea; Sophie Merk-Loretti; Charles-Edward Jefford; Panagiota Mikou; Irmgard Irminger-Finger; Anna Liossi; Jean-Louis Blouin; Sophie Dahoun
Journal:  Mol Cytogenet       Date:  2008-08-22       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.